Journal
NUCLEAR MEDICINE AND BIOLOGY
Volume 38, Issue 6, Pages 781-793Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nucmedbio.2011.01.010
Keywords
Hypoxia; PET; Antiangiogenic; MRI; Glioma; [F-18]-FMISO
Funding
- Centre National de la Recherche Scientifique (CNRS)
- French Ministere de l'Enseignement Superieur et de la Recherche
- University of Caen Lower Normandy (UCBN)
- Institut National contre le Cancer (INCa)
- Institut Lilly [8NL 1067 N085]
Ask authors/readers for more resources
Introduction: No direct proof has been brought to light in a link between hypoxic changes in glioma models and the effects of antiangiogenic treatments. Here, we assessed the sensitivity of the detection of hypoxia through the use of F-18-fluoromisonidazole positron emission tomography ([(18)]-FMISO PET) in response to the evolution of the tumor and its vasculature. Methods: Orthotopic glioma tumors were induced in rats after implantation of C6 or 9L cells. Sunitinib was administered from day (D) 17 to D24. At D17 and D24, multiparametric magnetic resonance imaging was performed to characterize tumor growth and vasculature. Hypoxia was assessed by [F-18]-FMISO PET. Results: We showed that brain hypoxic volumes are related to glioma volume and its vasculature and that an antiangiogenic treatment, leading to an increase in cerebral blood volume and a decrease in vessel permeability, is accompanied by a decrease in the degree of hypoxia. Conclusions: We propose that [F-18]-FMISO PET and multiparametric magnetic resonance imaging are pertinent complementary tools in the evaluation of the effects of an antiangiogenic treatment in glioma. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available